Evaluation of Sildenafil in Treatment of Pediatrics Pulmonary Hypertensio
Phase 1
- Conditions
- pediatric pulmonary hypertension.Primary pulmonary hypertension
- Registration Number
- IRCT138805222342N1
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
1) patients aged 1 month to 12 year 2) mean pulmonary artery pressure of = 25 mm Hg and a normal pulmonary capillary wedge pressure (PCWP). Exclusion criteria: 1) using other vasodilators such as epoprostanol, bosentan 2) patients with systemic blood pressure <50% for the same age
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction of pulmonary hypertension. Timepoint: 1 month. Method of measurement: Echocardiography.
- Secondary Outcome Measures
Name Time Method Adverse drug reactions. Timepoint: 1 month. Method of measurement: Question and exam.